Ambroxol for Lewy body dementia
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a medicine called ambroxol, which may slow down the progression of Lewy body dementia. It aims to see if it can improve memory, thinking, and movement symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of probable Lewy body dementia.
- You are over 50 years old.
- Your thinking and memory scores are within a specific range (MoCA score 18 to 24).
- You have a caregiver who can support you at least 4 days a week.
- Your current dementia, movement, or mood medications have been stable for at least 3 months.
- You do not have a pacemaker, metal implants in your head or eye, or other reasons that would make an MRI unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial follows people with probable Lewy body dementia over several years to see how the brain changes on MRI and on memory/thinking tests. It may help researchers understand disease progression and improve future care for Lewy body dementia.
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
This trial tests whether ambroxol (a mouth medicine) can help people with new or early dementia with Lewy bodies (DLB) or mild cognitive impairment linked to DLB. Participants take the medicine for about 18 months while the study tracks safety and changes over time.
This study tests an eHealth program together with a patient-and-caregiver support program, along with a medicine called ambroxol. It aims to see whether this combined approach is safe and helpful for people with dementia with Lewy bodies (or early memory changes from it).
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
Hear when a new Lewy Body Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.